



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 8, 2019

BSE Ltd.
Phiroze Jeejebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Sub : Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on December 31, 2018.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on December 31, 2018 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 12.00 noon and concluded at 2.10 pm.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
☎ +91 22 2431 5331 / 2431 5334
✉ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2018

(Rs. In lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		Year ended
		31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	35,212.05	40,427.40	30,474.20	1,12,236.62	93,589.87	1,25,473.42
2	Other Income	1,538.70	810.54	532.00	2,460.96	2,416.10	3,525.53
3	Total Income (1+2)	36,750.75	41,237.94	31,006.20	1,14,697.58	96,005.97	1,28,998.95
4	Expenses						
	a. Cost of materials consumed	11,049.81	11,451.18	10,081.54	33,601.07	26,930.51	38,701.68
	b. Purchases of stock-in-trade	2,346.28	2,907.92	2,279.03	7,723.59	8,576.95	9,304.46
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,964.69)	110.36	(1,676.13)	(2,263.92)	120.78	(38.81)
	d. Employee benefit expenses	6,475.90	6,626.02	5,310.67	19,039.62	16,192.63	21,730.93
	e. Finance Costs	126.93	71.57	61.07	325.73	246.24	341.36
	f. Depreciation and amortization expense	1,448.54	1,446.62	1,425.00	4,341.68	4,290.55	5,594.85
	g. Other Expenses	10,042.28	11,119.98	8,617.60	31,251.70	25,423.99	35,460.18
	Total Expenses (4)	29,525.05	33,733.65	26,098.78	94,019.47	81,781.65	1,11,094.65
5	Profit before Tax (3-4)	7,225.70	7,504.29	4,907.42	20,678.11	14,224.32	17,904.30
6	Tax expenses	2,588.35	2,360.28	1,522.36	6,689.70	3,630.11	5,104.16
7	Net Profit/(Loss) after Tax (5-6)	4,637.35	5,144.01	3,385.06	13,988.41	10,594.21	12,800.14
8	Other Comprehensive Income (net of Tax)	(61.80)	(61.81)	(13.10)	(185.41)	(93.79)	(241.63)
9	Total Comprehensive Income after Tax (7+8)	4,575.55	5,082.20	3,371.96	13,803.00	10,500.42	12,558.51
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	5.64	6.16	4.03	17.02	12.62	15.24
	(2) Diluted	5.64	6.16	4.03	17.02	12.62	15.24

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 8, 2019.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended on December 31, 2018 and they have not expressed modified opinion.
- The Company has one reportable segment viz. Pharmaceuticals.
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the period ended December 31, 2018 is not comparable with the previous corresponding period as the figures for the previous period was inclusive of excise duty.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : 08/02/2019


J. B. Mody
Chairman & Managing Director

Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Limited Review Report on Quarter and nine months ended Unaudited Standalone Financial Results of the J. B. Chemicals & Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals & Pharmaceuticals Limited

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **J. B. Chemicals & Pharmaceuticals Limited ("the Company")**, for the quarter and nine months ended December 31, 2018 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initiated by us for the purpose of identification.


The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended, read with the Circular is the responsibility of the Company's management and has been reviewed by Audit Committee and approved by the Board of Directors in their respective meeting held on February 8, 2019. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity' ('the Standard'), issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian Accounting Standard ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D N V & Co


Firm Registration No.: 102079W
Chartered Accountants


CA Bharat Jain
Partner

Membership No.: 100583

Place: Mumbai

Date: February 8, 2019





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2018

(Rs. In lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		Year ended
		31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	35,212.05	40,427.40	30,474.20	1,12,236.62	93,589.87	1,25,473.42
2	Other Income	1,538.70	810.54	532.00	2,460.96	2,416.10	3,525.53
3	Total Income (1+2)	36,750.75	41,237.94	31,006.20	1,14,697.58	96,005.97	1,28,998.95
4	Expenses						
	a. Cost of materials consumed	11,049.81	11,451.18	10,081.54	33,601.07	26,930.51	38,701.68
	b. Purchases of stock-in-trade	2,346.28	2,907.92	2,279.03	7,723.59	8,576.95	9,304.46
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,964.69)	110.36	(1,676.13)	(2,263.92)	120.78	(38.81)
	d. Employee benefit expenses	6,475.90	6,626.02	5,310.67	19,039.62	16,192.63	21,730.93
	e. Finance Costs	126.93	71.57	61.07	325.73	246.24	341.36
	f. Depreciation and amortization expense	1,448.54	1,446.62	1,425.00	4,341.68	4,290.55	5,594.85
	g. Other Expenses	10,042.28	11,119.98	8,617.60	31,251.70	25,423.99	35,460.18
	Total Expenses (4)	29,525.05	33,733.65	26,098.78	94,019.47	81,781.65	1,11,094.65
5	Profit before Tax (3-4)	7,225.70	7,504.29	4,907.42	20,678.11	14,224.32	17,904.30
6	Tax expenses	2,588.35	2,360.28	1,522.36	6,689.70	3,630.11	5,104.16
7	Net Profit/(Loss) after Tax (5-6)	4,637.35	5,144.01	3,385.06	13,988.41	10,594.21	12,800.14
8	Other Comprehensive Income (net of Tax)	(61.80)	(61.81)	(13.10)	(185.41)	(93.79)	(241.63)
9	Total Comprehensive Income after Tax (7+8)	4,575.55	5,082.20	3,371.96	13,803.00	10,500.42	12,558.51
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	5.64	6.16	4.03	17.02	12.62	15.24
	(2) Diluted	5.64	6.16	4.03	17.02	12.62	15.24

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 8, 2019.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended on December 31, 2018 and they have not expressed modified opinion.
- The Company has one reportable segment viz. Pharmaceuticals.
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the period ended December 31, 2018 is not comparable with the previous corresponding period as the figures for the previous period was inclusive of excise duty.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : 08/02/2019


J. B. Mody
Chairman & Managing Director



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380